枸橼酸托法替尼治疗难治性特应性皮炎的疗效观察。
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate.
机构信息
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
出版信息
J Am Acad Dermatol. 2015 Sep;73(3):395-9. doi: 10.1016/j.jaad.2015.06.045. Epub 2015 Jul 17.
BACKGROUND
Treatment of moderate to severe atopic dermatitis (AD) is often inadequate.
OBJECTIVE
We sought to evaluate the efficacy of the oral Janus kinase inhibitor tofacitinib citrate in the treatment of moderate to severe AD.
METHODS
Six consecutive patients with moderate to severe AD who had failed standard treatment were treated with tofacitinib citrate. Response to treatment was assessed using the Scoring of AD index.
RESULTS
Decreased body surface area involvement of dermatitis and decreased erythema, edema/papulation, lichenification, and excoriation were observed in all patients. The Scoring of AD index decreased by 66.6% from 36.5 to 12.2 (P < .05) during 8 to 29 weeks of treatment. There were no adverse events.
LIMITATIONS
Small sample size, lack of placebo control group, and the possibility of bias are limitations.
CONCLUSION
The oral Janus kinase inhibitor tofacitinib citrate may be beneficial in the treatment of moderate to severe AD.
背景
中重度特应性皮炎（AD）的治疗往往不充分。
目的
我们旨在评估口服 Janus 激酶抑制剂枸橼酸托法替布治疗中重度 AD 的疗效。
方法
对 6 例标准治疗失败的中重度 AD 患者采用枸橼酸托法替布进行治疗。采用 AD 严重程度评分（SCORAD）评估治疗反应。
结果
所有患者的皮炎体表面积受累程度和红斑、水肿/肿胀、苔藓样变和搔抓均有减轻。治疗 8 至 29 周后，SCORAD 评分从 36.5 降至 12.2（P＜0.05），下降了 66.6%。无不良反应发生。
局限性
样本量小，缺乏安慰剂对照组，可能存在偏倚，这些都是局限性。
结论
口服 Janus 激酶抑制剂枸橼酸托法替布可能有益于中重度 AD 的治疗。
Zotero 插件